BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:44 PM
 | 
Sep 11, 2012
 |  BC Extra  |  Company News

Price set for obesity drug Qsymia

Vivus Inc. (NASDAQ:VVUS) set the wholesale acquisition cost for once-daily obesity drug Qsymia phentermine/topiramate at $120 per month for the lowest dose and $183.90 per month for the highest dose, according to the Red Book. The company is set to launch the drug, which was approved in July, next quarter for adults with a BMI of...

Read the full 266 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >